The present invention is directed to a compound for use in reducing the symptoms of muscular dystrophy, wherein said compound has structural Formula I:wherein:said dashed line indicates an optional double bond；each R1 is hydrogen；R2 is selected from the group consisting of hydrogen and methyl；R3 is selected from the group consisting of hydrogen, hydroxyl, and methyl；or R2 and R3 may be taken together to form a double bond；R4 is -(CO)n(C(R5)(R6))m(R7)；R5 and R6 are independently selected from the groups consisting of hydrogen and C1-3 alkyl；R7 is selected from the group consisting of -N(R8)(R9) and -OR10；R8, and R9 are each independently selected from the group consisting of hydrogen, lower alkyl, and -(C(R5)2)pR11； or R8 and R9 may be taken together to form a heterocycloalkyl；R10 is selected from the group consisting of hydrogen, acyl, lower alkyl, and-(C(R5)2)pR11；R11 is selected from the group consisting of hydroxyl and amino；n is 0 or 1；m is an integer between 1 and 3；p is an integer between 1 and 3； andq is an integer between 1 and 4.
